Flyer

Health Science Journal

  • ISSN: 1791-809X
  • Journal h-index: 61
  • Journal CiteScore: 17.30
  • Journal Impact Factor: 18.23
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
Share This Page

Abstract

The Cytotoxic Molecule Ansamitocin P-3 Suppresses Cell Proliferation and Tumor Growth in Lung Carcinoma

Jinlei Ye, Shilei Wang, Ying Chen, Jie Tang, Zhilei Cui, Qiping Zheng and Lichun Sun

Lung cancer, mainly including small cell lung cancer (SCLC) and non-small lung cancer (non-SCLC, nSCLC), is a malignant and aggressive one and the leading cause of cancer-related death worldwide. Patients at late stages of lung cancers are usually treated with radiotherapy and chemotherapy. These traditional therapies displayed very limited benefits, with a poor five-year survival rate. The receptor-targeting therapy is becoming a new hot topic. Our previous studies demonstrated the receptor-targeting drug conjugates could enhance the anti-tumor efficacy of the free molecules via linking them to peptide vehicles. Presently, three chemical molecules camptothecin, AP-3 and colchicine were pre-tested for their cytotoxic activities in SCLC A549 cells and non-SCLC NCI-H69 cells. All these molecules displayed their potent effects on cell proliferation and cell apoptosis in both. Especially, AP-3 was extremely more potent than the other two. Our further in-vivo assay showed that AP-3 suppressed NCI-H69 tumor growth, but had a limited ability. A new strategy may be needed for AP-3 in SCLC treatment. Meanwhile, We found that somatostatin receptor type II (SSTR2) was highly expressed in SCLC cells, not non-SCLC cells. These findings may provide a golden opportunity to develop a SSTR2-targeting AP-3 somatostatin conjugate for SCLC treatments.